| Target Price | $39.78 | 
| Price | $35.83 | 
| Potential | 11.02% | 
| Number of Estimates | 27 | 
| 27 Analysts have issued a price target CSX 2026 . The average CSX target price is $39.78. This is 11.02% higher than the current stock price. The highest price target is $45.15 26.01% , the lowest is $27.27 23.89% . | |
| A rating was issued by 32 analysts: 23 Analysts recommend CSX to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the CSX stock has an average upside potential 2026 of 11.02% . Most analysts recommend the CSX stock at Purchase. | 
27 Analysts have issued a sales forecast CSX 2025 . The average CSX sales estimate is $14.4b . This is 1.70% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $15.0b 6.34% , the lowest is $13.8b 2.21% .
This results in the following potential growth metrics:
| 2024 | $14.5b | 0.80% | 
|---|---|---|
| 2025 | $14.4b | 1.22% | 
| 2026 | $15.0b | 4.44% | 
| 2027 | $15.6b | 3.86% | 
| 2028 | $16.3b | 4.36% | 
| 2029 | $17.0b | 4.74% | 
| 2030 | $17.4b | 2.21% | 
26 Analysts have issued an CSX EBITDA forecast 2025. The average CSX EBITDA estimate is $6.6b . This is 2.70% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $7.1b 9.53% , the lowest is $6.1b 5.08% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $7.0b | 1.02% | 
|---|---|---|
| 2025 | $6.6b | 5.01% | 
| 2026 | $7.2b | 8.48% | 
| 2027 | $7.6b | 5.53% | 
| 2028 | $8.1b | 6.67% | 
| 2029 | $8.5b | 4.35% | 
| 2024 | 48.14% | 0.22% | 
|---|---|---|
| 2025 | 46.29% | 3.85% | 
| 2026 | 48.09% | 3.89% | 
| 2027 | 48.86% | 1.60% | 
| 2028 | 49.94% | 2.21% | 
| 2029 | 49.75% | 0.38% | 
29 CSX Analysts have issued a net profit forecast 2025. The average CSX net profit estimate is $3.1b . This is 7.66% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.3b 14.54% , the lowest is $3.0b 2.50% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $3.5b | 5.40% | 
|---|---|---|
| 2025 | $3.1b | 9.96% | 
| 2026 | $3.6b | 14.89% | 
| 2027 | $4.0b | 11.28% | 
| 2028 | $4.5b | 11.60% | 
| 2029 | $4.9b | 10.41% | 
| 2030 | $5.5b | 11.97% | 
| 2024 | 23.87% | 4.64% | 
|---|---|---|
| 2025 | 21.75% | 8.86% | 
| 2026 | 23.93% | 10.02% | 
| 2027 | 25.64% | 7.15% | 
| 2028 | 27.41% | 6.90% | 
| 2029 | 28.90% | 5.44% | 
| 2030 | 31.66% | 9.55% | 
29 Analysts have issued a CSX forecast for earnings per share. The average CSX EPS is $1.68 . This is 8.39% higher than earnings per share in the financial year 2024. The highest EPS forecast is $1.79 15.48% , the lowest is $1.60 3.23% .
This results in the following potential growth metrics and future valuations:
| 2024 | $1.79 | 1.65% | 
|---|---|---|
| 2025 | $1.68 | 6.15% | 
| 2026 | $1.93 | 14.88% | 
| 2027 | $2.14 | 10.88% | 
| 2028 | $2.39 | 11.68% | 
| 2029 | $2.64 | 10.46% | 
| 2030 | $2.96 | 12.12% | 
| Current | 23.12 | 28.77% | 
|---|---|---|
| 2025 | 21.36 | 7.60% | 
| 2026 | 18.59 | 12.97% | 
| 2027 | 16.70 | 10.17% | 
| 2028 | 14.97 | 10.36% | 
| 2029 | 13.56 | 9.42% | 
| 2030 | 12.11 | 10.69% | 
Based on analysts' sales estimates for 2025, the CSX stock is valued at an EV/Sales of 5.94 and an P/S ratio of 4.65 .
This results in the following potential growth metrics and future valuations:
| Current | 6.04 | 9.03% | 
|---|---|---|
| 2025 | 5.94 | 1.72% | 
| 2026 | 5.68 | 4.25% | 
| 2027 | 5.47 | 3.72% | 
| 2028 | 5.24 | 4.18% | 
| 2029 | 5.01 | 4.53% | 
| 2030 | 4.90 | 2.17% | 
| Current | 4.72 | 7.71% | 
|---|---|---|
| 2025 | 4.65 | 1.67% | 
| 2026 | 4.45 | 4.25% | 
| 2027 | 4.28 | 3.72% | 
| 2028 | 4.10 | 4.18% | 
| 2029 | 3.92 | 4.53% | 
| 2030 | 3.83 | 2.16% | 
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| Baird | 
             Outperform 
            ➜ 
            Outperform 
           | 
          Unchanged | Oct 20 2025 | 
| JP Morgan | 
             Overweight 
            ➜ 
            Overweight 
           | 
          Unchanged | Oct 20 2025 | 
| Barclays | 
             Overweight 
            ➜ 
            Overweight 
           | 
          Unchanged | Oct 20 2025 | 
| Raymond James | 
             Outperform 
            ➜ 
            Outperform 
           | 
          Unchanged | Oct 17 2025 | 
| Evercore ISI Group | 
             Outperform 
            ➜ 
            Outperform 
           | 
          Unchanged | Oct 17 2025 | 
| TD Cowen | 
             Buy 
            ➜ 
            Buy 
           | 
          Unchanged | Oct 17 2025 | 
| Jefferies | 
             Buy 
            ➜ 
            Buy 
           | 
          Unchanged | Oct 17 2025 | 
| Analyst Rating | Date | 
|---|---|
| 
          
            Unchanged
          
           
            Baird:
             
        Outperform 
              ➜ 
              Outperform 
             | 
        Oct 20 2025 | 
| 
          
            Unchanged
          
           
            JP Morgan:
             
        Overweight 
              ➜ 
              Overweight 
             | 
        Oct 20 2025 | 
| 
          
            Unchanged
          
           
            Barclays:
             
        Overweight 
              ➜ 
              Overweight 
             | 
        Oct 20 2025 | 
| 
          
            Unchanged
          
           
            Raymond James:
             
        Outperform 
              ➜ 
              Outperform 
             | 
        Oct 17 2025 | 
| 
          
            Unchanged
          
           
            Evercore ISI Group:
             
        Outperform 
              ➜ 
              Outperform 
             | 
        Oct 17 2025 | 
| 
          
            Unchanged
          
           
            TD Cowen:
             
        Buy 
              ➜ 
              Buy 
             | 
        Oct 17 2025 | 
| 
          
            Unchanged
          
           
            Jefferies:
             
        Buy 
              ➜ 
              Buy 
             | 
        Oct 17 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


